2023
Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent NAFLD in Hispanic children
Welsh J, Pyo E, Huneault H, Ramirez L, Alazraki A, Alli R, Dunbar S, Khanna G, Knight-Scott J, Pimentel A, Reed B, Rodney-Somersall C, Santoro N, Umpierrez G, Vos M. Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent NAFLD in Hispanic children. Contemporary Clinical Trials 2023, 129: 107170. PMID: 37019180, PMCID: PMC10734403, DOI: 10.1016/j.cct.2023.107170.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseHispanic childrenFuture dietary guidelinesFatty liver diseasePrimary study outcomeLiver fat accumulationHigh-risk childrenSignificant hepatic steatosisOne-year interventionPercentile BMIElevated liverSecondary outcomesNAFLD preventionLiver diseaseLiver steatosisNAFLD pathogenesisPrevious diagnosisHepatic fatHepatic steatosisStudy protocolDietary guidelinesFat accumulationLiver disordersMetabolic markersEligibility criteriaClinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
Barbieri E, Santoro N, Umano G. Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity. Frontiers In Endocrinology 2023, 14: 1062341. PMID: 36733529, PMCID: PMC9887046, DOI: 10.3389/fendo.2023.1062341.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseInsulin resistancePediatric obesityDevelopment of NAFLDWhole-body insulin resistanceFatty liver diseaseType 2 diabetesAdipose tissue lipolysisCommon metabolic diseaseMetabolic complicationsClinical featuresLiver diseasePediatric populationTherapeutic optionsEctopic tissuePathophysiologic underpinningsTissue lipolysisRole of geneticsMetabolic diseasesObesityControl of insulinGrowth hormoneClinical implicationsDiseaseFatty acids
2020
Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth
Kravetz A, Testerman T, Galuppo B, Graf J, Pierpont B, Siebel S, Feinn R, Santoro N. Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth. The Journal Of Clinical Endocrinology & Metabolism 2020, 105: dgaa382. PMID: 32561908, PMCID: PMC7458486, DOI: 10.1210/clinem/dgaa382.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseHepatic fat fractionFatty liver diseasePNPLA3 rs738409Obese youthLiver diseaseGut microbiotaDifferent gut microbiota compositionNonalcoholic fatty liver diseaseOral glucose tolerance testPNPLA3 rs738409 variantPediatric obesity clinicGlucose tolerance testCross-sectional studyGut microbiota compositionAbdominal magnetic resonanceNAFLD statusRs738409 variantObesity clinicPNPLA3 genotypeObese childrenTolerance testBacteroidetes ratioCommon causeRs738409